A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers With Response and Resistance
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Ibrutinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 01 Sep 2016 Status changed from not yet recruiting to recruiting.
- 17 Aug 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2018.